A glypican-1-targeted antibody-drug conjugate exhibits potent tumor growth inhibition in glypican-1-positive pancreatic cancer and esophageal squamous cell carcinoma

An antibody-drug conjugate (ADC) is a promising therapeutic modality because selective and effective delivery of an anti-cancer drug is achieved by drug-conjugated antibody-targeting cancer antigen. Glypican 1 (GPC1) is highly expressed in malignant tumors, including pancreatic ductal adenocarcinoma...

Descripción completa

Detalles Bibliográficos
Autores principales: Munekage, Eri, Serada, Satoshi, Tsujii, Shigehiro, Yokota, Keiichiro, Kiuchi, Keita, Tominaga, Kenji, Fujimoto, Minoru, Kanda, Mizuki, Uemura, Sunao, Namikawa, Tsutomu, Nomura, Taisei, Murakami, Ichiro, Hanazaki, Kazuhiro, Naka, Tetsuji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8340053/
https://www.ncbi.nlm.nih.gov/pubmed/34332450
http://dx.doi.org/10.1016/j.neo.2021.07.006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8340053/
https://www.ncbi.nlm.nih.gov/pubmed/34332450
http://dx.doi.org/10.1016/j.neo.2021.07.006

Ejemplares similares